%3Aformat(webp)&w=3840&q=75)
Västra Hamnen Corporate Finance
Capital Markets Transactions and M&As
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
Recent research
%3Aformat(webp)&w=3840&q=75)
Xintela: Promising data for XSTEM in OA
Xintela recently announced positive interim data from its phase I/IIa study with XSTEM in knee osteoarthritis (OA). Data from 24 patients in all three dose levels have been analysed, 18 months after treatment. No serious safety or tolerability issues were recorded in the study and the company also received promising early efficacy data. Västra Hamnen contacted CEO Evy Lundgren Åkerlund for a comment.
%3Aformat(webp)&w=3840&q=75)
Xintela: Interim phase I/IIa data coming up
The interim analysis from the knee osteoarthritis study with XSTEM is expected by the end of Q1 2025. The readout is of great significance for Xintela’s lead project. In the difficult-to-heal leg ulcer (VLU) study, five patients have been recruited, four have completed the study. The company is investigating the possibility of moving to the next step, as no safety issues have been observed. There is no update regarding the process with EQGen Biomedical regarding EQSTEM. We expect the process with Region Östergötland to advance as planned. Minor adjustments to our model suggest a fair value of SEK 1.43 per share.
%3Aformat(webp)&w=3840&q=75)
Lipum: A busy year ahead
Just before the release of the year-end report, Lipum announced positive topline results from its phase I study with SOL-116 in rheumatoid arthritis. Now, the company is busy planning for the next clinical step, expected to start in Q1 2026. Financing, completing production of the drug candidate, study planning and filing the application are among the activities on the company’s agenda in 2025. Lipum is in transition to become a phase II company, which is an inflection point in terms of valuation. Until Lipum has reached some of its milestones, we keep our tight risk-adjustment, implying a fair value of SEK 15.83 per share.
%3Aformat(webp)&w=3840&q=75)
aXichem: Progress in Brazil and headwinds in the EU
The growing interest in aXivite and the continued establishment of aXiphen in Brazil will form the basis for aXichem's growth in 2025. At the beginning of the year, the company announced that it will carry out an additional efficacy study in order to be able to submit a complete application to EFSA when the study is completed. This will delay the launch of aXiphen in Europe compared to our previous forecast. At the same time, the company received an order of SEK 7 million from its distributor Chr. Olesen, which has led us to raise our estimates in Brazil. In sum, the changes result in a fair value of SEK 2.50 per share.
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75){kind=logo}
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
Market Focus
Market focus is our service for stock analysis of small and medium-sized listed companies. The service contributes to increased turnover in the share by increasing investors' awareness of the company and attention to current events. All our analyses are listed below.
Market Focus
Register for Market Focus updates
About us
We help our customers grow
Västra Hamnen Corporate Finance is an independent securities company that provides advice in connection with corporate transactions.
%3Aformat(webp)&w=3840&q=75)
"We love small companies and do our best every day to be their first choice in connection with listing processes and capitalizations."